Want to see JP:4502 full AI Analyst Report?
4502 Stock Chart & Stats
¥4222.00
-¥15.00(-0.36%)
At close: 4:00 PM EST
¥4222.00
-¥15.00(-0.36%)
Day’s Range― - ―
52-Week Range¥4,102.00 - ¥6,033.00
Previous CloseN/A
Volume3.70M
Average Volume (3M)4.35M
Market Cap
¥8.17T
Enterprise Value¥12.15T
Total Cash (Recent Filing)¥595.05B
Total Debt (Recent Filing)¥4.88T
Price to Earnings (P/E)42.3
Beta0.36
Next Earnings
Jul 30, 2026EPS Estimate
52.53Next Dividend Ex-DateN/A
Dividend Yield4.11%
Share Statistics
EPS (TTM)121.97
Shares Outstanding1,591,266,600
10 Day Avg. Volume4,483,280
30 Day Avg. Volume4,345,693
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)1.15
Price to Sales (P/S)1.98
P/FCF Ratio11.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥6,600.00Price Target Upside56.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)117.68
Revenue Forecast (FY)¥4.64T
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessFavorable Phase III results for orexin receptor agonist oveporexton for NT1 presented, showing significant improvement across NT1 symptoms.
Market PerformanceEntyvio continues to grow faster than the market, withstanding biosimilar step edits and branded competition.
Product DevelopmentSmooth progress on the late-stage development product is positive, with no serious treatment-related adverse events reported.
Bears Say
Government Pricing InitiativesEntyvio faces potential pricing headwinds via two government initiatives: MFN and IRA.
Pricing PressureMFN poses a threat not just because of its direct implications, but also because of the way in which prices are determined for 340b.
Takeda Pharmaceutical Co News
4502 FAQ
What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest stock price was ¥4102.00 and its highest was ¥6033.00 in the past 12 months.
What is Takeda Pharmaceutical Co Ltd’s market cap?
Takeda Pharmaceutical Co Ltd’s market cap is ¥8.17T.
When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
Takeda Pharmaceutical Co Ltd released its earnings results on May 13, 2026. The company reported -¥15.56 earnings per share for the quarter, beating the consensus estimate of -¥24.015 by ¥8.455.
Is Takeda Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Takeda Pharmaceutical Co Ltd pay dividends?
Takeda Pharmaceutical Co Ltd pays a Semiannually dividend of ¥101 which represents an annual dividend yield of 4.11%. See more information on Takeda Pharmaceutical Co Ltd dividends here
What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
Takeda Pharmaceutical Co Ltd’s EPS estimate is 52.53.
How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
Takeda Pharmaceutical Co Ltd has 1,591,266,600 shares outstanding.
What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
Takeda Pharmaceutical Co Ltd reported an EPS of -¥15.56 in its last earnings report, beating expectations of -¥24.015. Following the earnings report the stock price went up 0.464%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4502
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
4502 Company Deck
4502 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a constructive long-term outlook driven by a deep late-stage pipeline, multiple near-term regulatory catalysts (oveporexton, rusfertide, zasocitinib) and strong cash generation, supported by substantial cost savings and a clear transformation plan to fund launches and R&D. Near-term headwinds include a FY25 core revenue decline driven by VYVANSE LOE (≈JPY 150 billion), moderated growth in some legacy products (albumin, parts of PDT), restructuring costs (~JPY 170 billion in FY26) and guidance that anticipates core operating profit and EPS declines in FY26 as investments are made. On balance, the positive R&D achievements, clear launch roadmap, solid free cash flow and concrete efficiency targets outweigh the short-term financial pressures and execution risks.View all JP:4502 earnings summaries4502 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
¥6,600.00
▲(56.32% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
―
Shionogi & Co
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---








